User: Guest  Login
Title:

Protective effects of 4-aminopyridine in experimental optic neuritis and multiple sclerosis.

Document type:
Journal Article; Article
Author(s):
Dietrich, Michael; Koska, Valeria; Hecker, Christina; Göttle, Peter; Hilla, Alexander M; Heskamp, Annemarie; Lepka, Klaudia; Issberner, Andrea; Hallenberger, Angelika; Baksmeier, Christine; Steckel, Julia; Balk, Lisanne; Knier, Benjamin; Korn, Thomas; Havla, Joachim; Martínez-Lapiscina, Elena H; Solà-Valls, Nuria; Manogaran, Praveena; Olbert, Elisabeth D; Schippling, Sven; Cruz-Herranz, Andrés; Yiu, Hao; Button, Julia; Caldito, Natalia Gonzalez; von Gall, Charlotte; Mausberg, Anne K; Stettner, M...     »
Abstract:
Chronic disability in multiple sclerosis is linked to neuroaxonal degeneration. 4-aminopyridine (4-AP) is used and licensed as a symptomatic treatment to ameliorate ambulatory disability in multiple sclerosis. The presumed mode of action is via blockade of axonal voltage gated potassium channels, thereby enhancing conduction in demyelinated axons. In this study, we provide evidence that in addition to those symptomatic effects, 4-AP can prevent neuroaxonal loss in the CNS. Using in vivo optical...     »
Journal title abbreviation:
Brain
Year:
2020
Journal volume:
143
Journal issue:
4
Pages contribution:
1127-1142
Fulltext / DOI:
doi:10.1093/brain/awaa062
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/32293668
Print-ISSN:
0006-8950
TUM Institution:
Molekulare Immunologie (Prof. Knolle)
 BibTeX